Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

被引：0
|
作者：
Sarah E. Burnette
Emily Poehlein
Hui-Jie Lee
Jeremy Force
Kelly Westbrook
Heather N. Moore
机构：
[1] Atrium Health Wake Forest Baptist,Department of Pharmacy
[2] Duke University,Department of Biostatistics and Bioinformatics
[3] Duke University Cancer Institute,Department of Breast Oncology
[4] Duke University Medical Center,Department of Pharmacy
来源：
Breast Cancer Research and Treatment | 2023年 / 197卷
关键词：
Alpelisib; Metastatic breast cancer; Hormone-receptor positive; PIK3CA; Hyperglycemia; Rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：369 / 376
页数：7
相关论文
共 50 条
  • [31] Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Khanzada, Mikail
    Zaheer, Zaofashan
    Fatima, Eeshal
    Bakhtiar, Muhammad
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [32] Concordance of PIK3CA mutations in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: A systematic literature review
    Aguilar, Alejandra
    Dean, Joni
    Anderson, Elizabeth
    Mollon, Lea
    Davis, Lisa
    Warholak, Terri
    Aizer, Ayal
    Platt, Emma
    Bardiya, Aditya
    Tang, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe
    Guy Jerusalem
    Patrick Neven
    Nina Marinsek
    Jie Zhang
    Ravi Degun
    Giancarlo Benelli
    Stephen Saletan
    Jean-François Ricci
    Fabrice Andre
    BMC Cancer, 15
  • [34] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)
    Bello Roufai, D.
    Goncalves, A.
    de la Motte Rouge, T.
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I.
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-a
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    ONCOGENE, 2023, 42 (17) : 1417 - 1417
  • [35] Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor- positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
    Juric, Dejan
    Loibl, Sibylle
    Andre, Fabrice
    Mingorance, J. Ignacio Delgado
    Forget, Frederic
    Levy, Christelle
    Masuda, Norikazu
    Campone, Mario
    Conte, Pier Franco
    Iwata, Hiroji
    Mayer, Ingrid A.
    Rugo, Hope S.
    Wilke, Celine
    Ridolfi, Antonia
    Lteif, Agnes
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
    Llombart Cussac, A.
    Perez-Garcia, J. M.
    Blanch, S.
    Tolosa, P.
    Ruiz Borrego, M.
    Gion Cortes, M.
    Fernadez, A.
    Urruticoechea, A.
    Galve, E.
    Cueva Banuelos, J. F.
    Ponce, J.
    Alonso, J. L.
    Capelan, M.
    Martinez, E.
    Bermejo De Las Heras, B.
    Rojas, B.
    Martos, T.
    Lopez, A.
    Gomez-Peralta, F.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S77 - S77
  • [37] Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue
    Schmidt, Carolin
    Stoehr, Robert
    Dimitrova, Lora
    Beckmann, Matthias W.
    Ruebner, Matthias
    Fasching, Peter A.
    Denkert, Carsten
    Lehmann, Ulrich
    Vollbrecht, Claudia
    Haller, Florian
    Hartmann, Arndt
    Erber, Ramona
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (07): : 624 - 637
  • [38] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Burris, Howard A., III
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
  • [39] Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer
    Jason A. Mouabbi
    C. Kent Osborne
    Rachel Schiff
    Mothaffar F. Rimawi
    Breast Cancer Research and Treatment, 2021, 190 : 189 - 201
  • [40] EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
    Hurvitz, S. A.
    Chia, S. K. L.
    Ciruelos, E. M.
    Hu, X.
    Im, S-A.
    Janni, W.
    Jerusalem, G.
    Lacouture, M.
    O'Regan, R.
    Rugo, H. S.
    Yap, Y. S.
    Ghaznawi, F.
    Han, Y.
    Su, F.
    Chandarlapaty, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S389 - S390
12345